Stockscreener 앱 받기
0.2609
2.58%
-0.0069
전일 마감가:
$0.2678
열려 있는:
$0.27
하루 거래량:
137.73K
Relative Volume:
0.18
시가총액:
$19.41M
수익:
-
순이익/손실:
$-31.88M
주가수익비율:
-0.3479
EPS:
-0.75
순현금흐름:
$-25.20M
1주 성능:
-9.03%
1개월 성능:
-3.01%
6개월 성능:
-68.52%
1년 성능:
-80.67%
1일 변동 폭
$0.25
$0.27
1주일 범위
$0.25
$0.285
52주 변동 폭
$0.217
$1.74
인에잇바이오 Stock (INAB) Company Profile
명칭
In 8 Bio Inc
전화
(646) 600-6438
주소
EMPIRE STATE BUILDING, NEW YORK
INAB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INAB
In 8 Bio Inc
|
0.266 | 19.41M | 0 | -31.88M | -25.20M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
439.82 | 113.70B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.97 | 75.52B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
663.38 | 39.78B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.34 | 35.34B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
122.33 | 29.05B | 3.30B | -501.07M | 1.03B | -2.1146 |
인에잇바이오 Stock (INAB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-03-18 | 개시 | Laidlaw | Buy |
| 2022-08-30 | 개시 | H.C. Wainwright | Buy |
인에잇바이오 주식(INAB)의 최신 뉴스
Palisade Bio Selected for Poster Presentation at the 2025 Crohn’s & Colitis Congress - Yahoo Finance UK
Breakeven On The Horizon For Belite Bio, Inc (NASDAQ:BLTE) - Yahoo Finance UK
Cabaletta Bio Discloses Unaudited Cash and Cash Equivalents of $164 Million as of December 31, 2024 - Defense World
Palisade Bio Completes All Five SAD Cohorts and Advances to - GlobeNewswire
Vyant Bio (OTCMKTS:VYNT) Shares Up 7.8% – Time to Buy? - Defense World
Mustang Bio Announces Reverse Stock Split - GlobeNewswire
Passage Bio (NASDAQ:PASG) Announces Restructuring Plan and Financial Update - Defense World
Annovis Bio, Inc. (NYSE:ANVS) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Cadenza Bio, Inc. Announces Members of the Women's Health Scientific Advisory Board - Chicago Star Media
Pivot Bio Announces Ryan Degnan as Head of Growth - PR Newswire
Adicet Bio Provides Corporate Update - TradingView
Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones - The Bakersfield Californian
7 Best Biotech Stocks to Buy for 2025 | Investing - U.S News & World Report Money
INmune Bio: Phase 2 Trial In Alzheimer's Disease Is My Highest Risk-Reward Bet Of 2025 - Seeking Alpha
Geode Capital Management LLC Increases Holdings in Nuvation Bio Inc. (NYSE:NUVB) - MarketBeat
KALA BIO Announces Private Placement Agreement with Institutional Investors - Defense World
KALA BIO Announces $10,750,000 Private Placement - GlobeNewswire
bluebird bio, Inc. (BLUE): Is This Gene Therapy Stock a Good Buy Right Now? - Yahoo Finance
GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds - Yahoo Finance
**BioAtla Updates Corporate Presentation in 8-K Filing** - Defense World
Tolerance Bio, Inc. Announces Scientific Advisory Board and Completion of $20.2 Million Seed Round to Advance Thymus-Based Therapies for Immune-Mediated Diseases - Business Wire
Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board - GlobeNewswire
Annovis Bio 8-K Filing Reveals Investor Update and Presentation Details - Defense World
Attendee List for BevNET Live Winter 2024 - BevNET.com
INmune Bio Inc. Completes Repayment of Silicon Valley Bank Debt - The Manila Times
INmune Bio Strengthens Balance Sheet Ahead of Crucial Alzheimer's Trial Data, Clears $15M Debt - StockTitan
Suven Pharma acquires 56% stake in US-based NJ Bio - The Times of India
Hyderabad's Suven to acquire controlling stake in Princeton based NJ Bio, Inc - Deccan Herald
GRI Bio to Participate in the Virtual Investor Closing Bell Series - GlobeNewswire
PRUDENTIAL FINANCIAL INC's Strategic Acquisition of Cabaletta Bio Inc Shares - GuruFocus.com
bluebird bio Announces 1-for-20 Reverse Stock Split - Business Wire
/C O R R E C T I O N -- Today's Marketplace/ - Quantisnow
Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects - GlobeNewswire
KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire
Kronos Bio : Management Change/Compensation Form 8 K - Marketscreener.com
Tevogen Bio Prepares Organizational Readiness to Support Company’s Growth Strategy - GlobeNewswire
Annovis to Host Year-End Investor Webcast on December 11, 2024 - Quantisnow
Advantage Therapeutics Inc. Announces Formation of Klothea Bio, Inc. to Advance Research and Development of Klotho Protein for Age-Related Therapeutics - Yahoo Finance
GRI Bio Showcases GRI-0621's Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF) - The Manila Times
GRI Bio Showcases GRI-0621’s Potential to Reduce - GlobeNewswire
Palisade Bio to Present Preclinical Results for PALI-2108 - GlobeNewswire
10 Biggest Biotechnology Companies - Investopedia
TāStation®'s analytical power used to resolve a central question about sweet taste perception - EurekAlert
Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024 - The Manila Times
Intevac (NASDAQ: IVAC) Enters into Letter Agreement with Palogic Value Management, L.P.Santa Clara, CA, November 13, 2024 – Intevac, Inc. (NASDAQ: IVAC) disclosed today in a Form 8-K filing that on November 8, 2024, the company entered into a letter - Defense World
Sound Point Meridian Capital, Inc. (NYSE: SPMC) Announces Financial Results for Quarter Ended September 30, 2024 - Defense World
Roth CH Acquisition II Files 8-K Report with SEC Detailing Company Updates and Investor Presentation - Defense World
Capricor Therapeutics Announces Financial Results for Third Quarter 2024 and Strategic DevelopmentsSAN DIEGO, November 13, 2024 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR) recently disclosed its financial outcomes for the third - Defense World
Predictive Oncology Inc. Issues Press Release Detailing Financial Results for Q3 2024Predictive Oncology Inc., a leading biopharmaceutical company, released a pivotal press release detailing its financial results for the quarter ending September 30 - Defense World
Broadwind, Inc. Reports Financial Results for Quarter Ending September 30, 2024 - Defense World
Gritstone bio : Bankruptcy Form 8 K - Marketscreener.com
인에잇바이오 (INAB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.69%
4.93%
자본화:
|
볼륨(24시간):